Our CEO, Dr James Garner recently conducted a video interview with Share Café following Kazia’s announcement of a collaboration with Dana-Farber Cancer Institute to investigate the use of paxalisib in primary central nervous system (CNS) lymphoma, a potential new indication for the drug.
In the interview, Dr Garner discusses:
- The significance of the collaboration in that it is the sixth ongoing clinical trial of paxalisib in different forms of brain cancer
- Why Kazia is exploring the use of paxalisib in different forms of brain cancer and the potential advantages of the drug compared to existing therapies for primary central nervous system (CNS) lymphoma
- The rationale behind Kazia’s investigator-led clinical trial strategy for paxalisib
- Kazia’s upcoming strategic milestones over the next 6 to 12 months
Watch the video interview here.
